Otifex Therapeutics Pty Ltd is an Australian specialty pharmaceutical company established to develop a novel nasal spray product based on betahistine, a pharmaceutical widely used in tablet form for the treatment of Meniere's Disease and balance-related disorders.Otifex was spun out from The University of Melbourne and Murdoch Children's Research Institute in 2009 and in 2010 the Company attracted seed investment funding from Uniseed and the Medical Research Commercialisation Fund managed by Brandon Capital Partners.In February 2017, key assets related to the Otifex nasal spray product were acquired by NASDAQ-listed company Auris Medical AG, who are developing the product under the code AM-125 for Meniere's Disease and Vestibular Vertigo.